Antisense Oligonucleotide Therapeutics market is projected

Visiongain has published a new report entitled Antisense Oligonucleotide Therapeutics 2022-2032. It includes profiles of Antisense Oligonucleotide Therapeutics and Forecasts Market Segment by Therapeutic Area (Genetic Disorders, Neurological Disorders, Oncological Disorders, Metabolic Disorders, Ophthalmic Disorders, Others), Market Segment by Type (Ribozyme, DNAzyme, Anti-Gene, Other Types), Market Segment by Route of Administration (Pulmonary Delivery, Intravenous Injections, Intradermal Injections, Intraperitoneal Injections, Topical Delivery, Others), plus COVID-19 Impact Analysis and Recovery Pattern Analysis (“V”-shaped, “W”-shaped, “U”-shaped, “L”-shaped), Profiles of Leading Companies, Region and Country.

The antisense oligonucleotide therapeutics market was valued at US$17.46 billion in 2021 and is projected to grow at a CAGR of 13.71% during the forecast period 2022-2032.

Advancements in Technology to Offer Lucrative Growth Opportunities for Market Players
Despite the fact that antisense technology has not yet reached its full potential, it has made enormous progress to date. There are still more open issues that call for technological advancement. The development of first-generation phosphorothioate oligodeoxynucleotides is an excellent resource and priceless pharmacological tool that has demonstrated to the patient the possibility of new medicines. Better patient therapy will be the outcome of further development of superior second- and third-generation antisense oligonucleotides with unique formulation. Even while antisense technology has advanced significantly, there are still many unanswered questions about it and potential to enhance the platform even more. With the use of this technology, hitherto untreatable diseases now have treatments and hope. This therapeutic method has not been inaccessible to the general populace due to its expensive cost. Future advancements in this technology may aid in discovering a better and…